clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Svensson M et al. | Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. | 2002 | Antimicrob. Agents Chemother. | pmid:12069981 |
| Comley JC and Sterling AM | Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. | 1995 | Antimicrob. Agents Chemother. | pmid:7785975 |
| Struillou L et al. | Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. | 1995 | Antimicrob. Agents Chemother. | pmid:7785988 |
| Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
| Fish DN et al. | Penetration of clarithromycin into lung tissues from patients undergoing lung resection. | 1994 | Antimicrob. Agents Chemother. | pmid:8031063 |
| Ishida K et al. | In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. | 1994 | Antimicrob. Agents Chemother. | pmid:8031048 |
| Alder J et al. | Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. | 1993 | Antimicrob. Agents Chemother. | pmid:8494384 |
| Alder J et al. | Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. | 1993 | Antimicrob. Agents Chemother. | pmid:8328782 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Mor N and Heifets L | Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8328792 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Meier A et al. | Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. | 1994 | Antimicrob. Agents Chemother. | pmid:8192472 |
| Khan AA et al. | Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. | 1997 | Antimicrob. Agents Chemother. | pmid:9145840 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Collins L and Franzblau SG | Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | 1997 | Antimicrob. Agents Chemother. | pmid:9145860 |
| Chan GP et al. | Clinical trial of clarithromycin for lepromatous leprosy. | 1994 | Antimicrob. Agents Chemother. | pmid:8203847 |
| Lounis N et al. | Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. | 1997 | Antimicrob. Agents Chemother. | pmid:9145892 |
| Cavalieri SJ et al. | Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:7492101 |
| Beeton ML et al. | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. | 2009 | Antimicrob. Agents Chemother. | pmid:19273669 |
| Rimbara E et al. | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. | 2008 | Antimicrob. Agents Chemother. | pmid:18606842 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Khan R et al. | T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. | 2004 | Antimicrob. Agents Chemother. | pmid:15328128 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Mor N and Heifets L | MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. | 1993 | Antimicrob. Agents Chemother. | pmid:8431006 |
| Tomioka H et al. | In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. | 1993 | Antimicrob. Agents Chemother. | pmid:8431020 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Amsden GW et al. | Oral cimetidine prolongs clarithromycin absorption. | 1998 | Antimicrob. Agents Chemother. | pmid:9660986 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Hotomi M et al. | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17698631 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Stone GG et al. | A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9056021 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Dai G et al. | Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:16048962 |
| Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
| Klemens SP et al. | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1336945 |
| van Doorn LJ et al. | Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. | 2001 | Antimicrob. Agents Chemother. | pmid:11302817 |
| Piccolomini R et al. | In vitro activity of clarithromycin against intracellular Helicobacter pylori. | 2001 | Antimicrob. Agents Chemother. | pmid:11302831 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Bernut A et al. | In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. | 2014 | Antimicrob. Agents Chemother. | pmid:24798271 |
| Spyridaki I et al. | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. | 2009 | Antimicrob. Agents Chemother. | pmid:19332671 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |
| Aoki D et al. | Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production. | Anticancer Res. | pmid:15816530 | |
| Ohara T et al. | Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. | 2004 Nov-Dec | Anticancer Res. | pmid:15736403 |
| Gintovt EA | [Use of clarithromycin in the treatment of atopic dermatitis complicated by staphylococcal infection]. | 2004 | Antibiot. Khimioter. | pmid:15164520 |
| Vasil'ev IuV and Zvenigorodskaia LA | [Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer]. | 2002 | Antibiot. Khimioter. | pmid:12365323 |
| Iakovlev EA et al. | [Present stage of chemotherapy and chemoprophylaxis of rickettsiosis and Q fever]. | 2011 | Antibiot. Khimioter. | pmid:22856156 |
| Iakovlev VP | [New semisynthetic macrolides. Clarithromycin--its importance in the current therapy of bacterial infections]. | 1999 | Antibiot. Khimioter. | pmid:10635418 |
| Evdokimova AG et al. | [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. | 2013 | Antibiot. Khimioter. | pmid:24640139 |
| Iakovlev VP et al. | [Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections]. | 2000 | Antibiot. Khimioter. | pmid:11210297 |
| Shcherbakov PL | [Clarithromycin in eradication therapy of helicobacter infections in children]. | 2001 | Antibiot. Khimioter. | pmid:11871315 |
| Sazykin IuO et al. | [Clarithromycin and tumor chemotherapy]. | 2000 | Antibiot. Khimioter. | pmid:11210301 |
| Iutanova NS | [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia]. | 2004 | Antibiot. Khimioter. | pmid:15344392 |
| Budanov SV and Vasil'ev AN | [Clarithromycin: specific features of antimicrobial spectrum and clinical use]. | 2004 | Antibiot. Khimioter. | pmid:15285409 |
| Guchev IA et al. | [Evaluation of clarithromycin efficacy in the treatment of community-acquired pneumonia on the basis of the Binax NOW test results (a prospective open trial)]. | 2002 | Antibiot. Khimioter. | pmid:12619516 |
| Hiramatsu M et al. | Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. | 2012 | Ann. Thorac. Surg. | pmid:22119119 |
| Fan X et al. | Lung perfusion with clarithromycin ameliorates lung function after cardiopulmonary bypass. | 2006 | Ann. Thorac. Surg. | pmid:16488691 |
| Nelson KG et al. | Results of operation in Mycobacterium avium-intracellulare lung disease. | 1998 | Ann. Thorac. Surg. | pmid:9725364 |
| Kadir IS et al. | Recurrent acute rheumatic fever: a forgotten diagnosis? | 2004 | Ann. Thorac. Surg. | pmid:15276555 |
| Bossert T et al. | Successful management of two heart transplant recipients with mycobacterial pulmonary infections. | 2005 | Ann. Thorac. Surg. | pmid:16039241 |
| Watanabe M et al. | Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. | 2006 | Ann. Thorac. Surg. | pmid:16731124 |
| Callaghan R and Allen M | Mycobacterium malmoense infection of the knee. | 2003 | Ann. Rheum. Dis. | pmid:14583565 |
| Rhee CS et al. | Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. | 2000 | Ann. Otol. Rhinol. Laryngol. | pmid:10823478 |
| Heffernan CB et al. | Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. | 2018 | Ann. Otol. Rhinol. Laryngol. | pmid:30032669 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Mullin D et al. | Mycobacterium chelonae infections involving the head and neck. | 2009 | Ann. Otol. Rhinol. Laryngol. | pmid:19894399 |
| Ferreri AJ et al. | High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial. | 2015 | Ann. Oncol. | pmid:25935794 |
| Di Raimondo F et al. | Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? | 2007 | Ann. Oncol. | pmid:17065587 |
| Trotti LM et al. | Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. | 2015 | Ann. Neurol. | pmid:26094838 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Musher DM | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7778830 |
| van der Meer JT and Danner SA | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7778831 |
| Patel AM et al. | Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. | 2013 | Ann. Intern. Med. | pmid:23778904 |
| Steinman MA et al. | Changing use of antibiotics in community-based outpatient practice, 1991-1999. | 2003 | Ann. Intern. Med. | pmid:12667022 |
| Chaisson RE et al. | Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. | 1994 | Ann. Intern. Med. | pmid:7978715 |
| Goldberger M and Masur H | Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. | 1994 | Ann. Intern. Med. | pmid:7978725 |
| Shafran SD et al. | Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. | 2002 | Ann. Intern. Med. | pmid:12416943 |
| Vaira D et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. | 2007 | Ann. Intern. Med. | pmid:17438314 |
| Singh N and Yu VL | Clarithromycin therapy for Mycobacterium avium complex bacteremia. | 1995 | Ann. Intern. Med. | pmid:7632282 |
| Wallace RJ et al. | Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. | 1993 | Ann. Intern. Med. | pmid:8357113 |
| Neu HC | New macrolide antibiotics: azithromycin and clarithromycin. | 1992 | Ann. Intern. Med. | pmid:1310839 |
| Sjölund M et al. | Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. | 2003 | Ann. Intern. Med. | pmid:13679325 |
| Summaries for patients. Past antibiotic use affects resistance and outcomes of Helicobacter pylori infection. | 2003 | Ann. Intern. Med. | pmid:13679344 | |
| Summaries for patients. Effects of antibiotic treatment for Helicobacter pylori on normal bowel bacteria. | 2003 | Ann. Intern. Med. | pmid:13679347 | |
| Liviu L et al. | Pancreatitis induced by clarithromycin. | 1996 | Ann. Intern. Med. | pmid:8849171 |
| Seow J and Chew FT | Risk factors for Helicobacter pylori resistance. | 2004 | Ann. Intern. Med. | pmid:15172911 |
| Jafri NS et al. | Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. | 2008 | Ann. Intern. Med. | pmid:18490667 |
| Berk SL | New macrolide antibiotics. | 1992 | Ann. Intern. Med. | pmid:1386966 |
| Summaries for patients. Factors associated with Helicobacter pylori infections in the United States that are resistant to usual antibiotics. | 2002 | Ann. Intern. Med. | pmid:11797613 | |
| Meyer JM et al. | Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. | 2002 | Ann. Intern. Med. | pmid:11777360 |
| Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |